geoscience.net logo
+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Parkinson's disease and sleep


, : Parkinson's disease and sleep. Neurologic Clinics 23(4): 1187-1208

Sleep disorders are common in PD and many factors can contribute to disturbed nocturnal sleep and daytime sleepiness. Factors contributing to sleep disturbance include the presence of insomnia, mood or anxiety disorders, dementia, specific sleep disorders, PD motor disorders, and the effects of PD or medications. Patients who have PD should be interrogated about sleep disturbance and daytime sleepiness and preferably, because of underestimation of the severity of sleepiness or lack of awareness, patients should be interviewed in the presence of a close friend or relative. The ability to drive, if sleepiness is present, should be assessed and appropriate recommendations made. Treatment of sleepiness involves treating any underlying sleep disturbance and may involve the use of stimulant or alerting medications in the daytime.

US$19.90

PMID: 16243622

DOI: 10.1016/j.ncl.2005.05.001


Other references

Menon, K.; Viswanathan, N.B.lasubramanian, S., 1978: Job content and context factors in job satisfaction of deputy agricultural officers. Madras agricultural journal 65(10): 654-657

Manowska, W.; Krzywicka, H.; Janowska, J., 1979: Bactericidal effect of disinfectants on various strains of Mycobacterium tuberculosis. Przeglad Epidemiologiczny 33(2): 293-299

Hamzehee, F.; Pourayoubi, M.; Nečas, M.; Choquesillo-Lazarte, D., 2017: Extensive analysis of N-H...O hydrogen bonding in four classes of phosphorus compounds: a combined experimental and database study. The N-H...O hydrogen bond is the characteristic interaction in the crystal structures of N-benzyl-P-phenyl-N'-(p-tolyl)phosphonic diamide, C<sub>20</sub>H<sub>21</sub>N<sub>2</sub>OP or (C<sub>6</s...

Wakim, J.; Goudenege, D.; Perrot, R.; Gueguen, N.; Desquiret-Dumas, V.; Chao de la Barca, J.Manuel.; Dalla Rosa, I.; Manero, F.; Le Mao, M.; Chupin, S.; Chevrollier, A.; Procaccio, V.; Bonneau, D.; Logan, D.C.; Reynier, P.; Lenaers, G.; Khiati, S., 2017: CLUH couples mitochondrial distribution to the energetic and metabolic status. Mitochondrial dynamics and distribution are critical for supplying ATP in response to energy demand. CLUH is a protein involved in mitochondrial distribution whose dysfunction leads to mitochondrial clustering, the metabolic consequences of which...

Chung, J.Lim.; Lim, E.Hye.; Song, S.Wroul.; Kim, B.Yeop.; Lee, J.H.; Mah, F.S.; Seo, K.Yul., 2014: Comparative intraocular penetration of 4 fluoroquinolones after topical instillation. To compare the intraocular penetration of 4 fluoroquinolone eye drops after topical instillation into rabbit eyes. The tested drugs were levofloxacin 1.5% (LVFX), gatifloxacin 0.3%, moxifloxacin 0.5% (MFLX), and besifloxacin 0.6% (BFLX). Forty-eig...

Brodzinski, H.; Ruddy, R.M., 2009: Review of new and newly discovered respiratory tract viruses in children. Respiratory tract viral infection continues to be among the most common reasons for emergency department visits and hospitalization of children, particularly infants younger than 1 year, in the United States. Throughout the years, clinicians have...

Karaca, M.; Kocabas, A.; Kabakci, T., 1971: Oral contraceptives in haemophilia. Lancet 1(7706): 974-974

George, S.A.; Ferguson, J., 1992: Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects. Thirty-nine patients with psoriasis undergoing PUVA participated in a prospective double-blind study of acute non-phototoxic adverse effects comparing the liquid formulations of 8-methoxypsoralen (0.6 mg/kg) and 5-methoxypsoralen (1.2 mg/kg). A mu...

Bloomberg, J.R., 1997: AxiomReg.-a new soil-applied graminicide for maize and soyabeans. To enhance small-seeded dicotyledenous weed control, FOE 5043 ((N-(4-fluorphenyl)-N-(1-methyl-ethyl)-2-[5-(trifluormethyl)-1,3,4-thiadiazol-2-yl oxy] acetamid)) has been combined with a low rate of metribuzin and sold under the trade name Axiom. B...

Pau, H-W., 2009: The birth of ENT happened in Rostock. Hno 57(5): 417-420